COVID-19 is a fast-moving pandemic. The infection has a mortality rate of 3-6%. Patients with underlying CVD are at higher risk of contracting COVID-19 and have a worse prognosis.
Our experts from Wuhan China and Singapore have shared clinical experiences from frontline China on management of COVID-19 patients with underlying heart disease. Topics include:
Diagnosis to management of COVID-19 patients with underlying CVD: Learnings from China
COVID-19 and Anti-hypertensive Drugs
Clinical Case sharing – experience from Singapore
Dr. Zhou Ning, Wuhan China
Deputy Chief Physician, Associate Professor, Postgraduate Supervisor
Department of Cardiovascular Medicine, Tongji Hospital, Tongji Medical College,
Huazhong University of Science and Technology.
Dr Ling Li Min, Singapore
Infectious Diseases Physician National Centre for Infectious Diseases (NCID) and Tan Tock Seng Hospital (TTSH), Singapore
Moderator
Dr. Jack Tan, Singapore
Deputy Head of Cardiology and Director of the Coronary Care Unit, National Heart Centre Singapore
Head of Cardiology, Sengkang Hospital
President, Asian Pacific Society of Cardiology
Panelists
Prof Koji Hasegawa, Japan
Director of the Division of Translational Research,
National Hospital Organization Kyoto Medical Center
Dr LAM ho, Hong Kong
Consultant, Department of Medicine and Geriatrics, Cath Lab Director, Tuen Mun Hospital, Hong Kong. Council Member, Hong Kong Medical Association.
Participants can be Cardiologists, ED physicians, Intensivists, Respiratory specialists, Lab specialists, Internists and physicians who are involved in critical care.
Learning from sharing on clinical experience from frontline China on management of COVID-19 patients with underlying heart disease.
Learning from Clinical Case sharing by a Cardiologist at the epicenter of the outbreak, Wuhan China.
Panel discussion session including Q&A.
COVID-19 and the Heart: Experiences from the Frontline